Answers are grounded in this paper and cite their sources.
We investigated the binding form of IgE to platelets and the relationship between IgE and platelet function. When the paraformaldehyde (PFA)-fixed platelets were incubated with the IgE-protein from human myeloma (M-IgE), the platelet-associated IgE (PAIgE) of Glanzmann's thrombasthenic platelets was significantly less than that of healthy control. The binding of M-IgE to the healthy PFA-fixed platelets was in-hibited by the pretreatment of the platelets with monoclonal anti-GPIIb/IIIa complex antibody or Arg-Gly-Asp-Ser (RGDS), but not monoclonal anti-GP I b antibody or heat aggregated IgG. When the unfixed platelets which had been activated with PAF or ADP were incubated with the M-IgE, the PAIgE increased significantly. The increased PAIgE hardly effected on not only the platelet aggregation or platelet secretion but also the increase of [Ca2+]i by activation. These results suggest that IgE binds to not the Fc-receptor but the GPIIb/IIIa-related receptor on the platelet surface. This binding increases with the platelet activation, whereas the increased IgE dose not appear to effect on the platelet function.
No takes yet. Share an insight, caveat, or question.
Nomura et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: